Anzeige
Mehr »
Mittwoch, 09.09.2026 - Börsentäglich über 12.000 News
Gediegen Kupfer im Bohrkern - Metall in reiner Form!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
183 Leser
Artikel bewerten:
(0)

Accumulus Technologies Announces Acquisition by Eir Partners to Accelerate Next Phase of Growth

Strategic investment will support continued advancement of the Accumulus platform and expand global adoption across the life sciences regulatory ecosystem

SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Accumulus Technologies today announced that it has been acquired by Eir Partners, an investment firm specializing in healthcare technology and tech-enabled services.

The acquisition marks the next phase in Accumulus' growth and builds on the company's 2025 spinout from nonprofit Accumulus Synergy. That spinout established Accumulus Technologies as a standalone commercial organization with the ability to raise capital, form strategic partnerships and scale its platform. With Eir Partners' backing, Accumulus plans to increase investment in its technology and capabilities, support continued global adoption and expand the value it delivers across the regulatory ecosystem.

"This acquisition is an important milestone for Accumulus and a strong endorsement of the progress we have made and the opportunity ahead," said Francisco Nogueira, Chief Executive Officer of Accumulus Technologies. "Eir Partners understands the healthcare technology landscape and shares our vision for a more connected and efficient regulatory ecosystem that helps medicines reach more patients more quickly. Together, we can move faster and expand our impact while staying true to the mission at the heart of Accumulus."

The Accumulus platform enables life sciences organizations and regulatory authorities to collaborate and exchange information more efficiently in a secure, cloud-based environment. Today, more than 75 regulatory authorities are connected to the platform, with growing engagement across industry. Accumulus will continue to operate under its existing leadership and remain focused on serving the global life sciences regulatory ecosystem.

"Accumulus occupies a unique position at the intersection of life sciences, technology and global regulation," said Brett Carlson, Founder and Chief Executive Officer of Eir Partners. "Its purpose-built platform, engagement across industry and regulatory authorities, and potential to transform how life sciences companies and regulatory authorities interact make Accumulus a compelling partnership for Eir. We look forward to supporting the Accumulus team as they advance the platform and extend its impact."

Terms of the transaction were not disclosed. EP Securities, LLC served as exclusive financial advisor to Accumulus Technologies in connection with the transaction. TripleTree, LLC served as exclusive financial advisor to Eir Partners in connection with the transaction.

About Accumulus Technologies
Accumulus Technologies is a leading cloud technology provider reimagining how life sciences organizations and national regulatory authorities work together to accelerate the drug development lifecycle, from drug discovery through global availability. Spun out from nonprofit Accumulus Synergy in 2025, its secure, purpose-built SaaS platform enables real-time collaboration and continuous data streaming, powering faster decisions, global alignment and accelerated access to therapies for patients worldwide. With a focus on innovation, trust and impact, Accumulus Technologies is connecting the global regulatory ecosystem through a single, scalable solution.

About Eir Partners
Eir Partners Capital is a Miami-based private equity firm focused on healthcare technology and tech-enabled services. Founded in 2015, Eir has partnered with entrepreneurs and management teams to create scaled, strategically differentiated platforms across payer, provider, employer and pharma technology sectors. The firm's hands-on approach combines operational insight with deep industry relationships to drive long-term value. Targeted stages of investment include growth equity through control buyouts, with equity check sizes ranging from $40 million to $150 million or larger with co-investments. For more information, visit Eir Partners' website or LinkedIn page.

Media Contacts
Accumulus Technologies
Allison Mari
media@accumulustech.com
540-907-6053

Eir Partners
Rich Myers, Profile Advisors
rmyers@profileadvisors.com


© 2026 GlobeNewswire (Europe)
KI braucht Strom
Halbleiter, Speicherchips und Rechenzentren haben Anlegern im KI-Boom bereits enorme Gewinne beschert. Doch jetzt zeichnet sich mit der benötigten Energie der nächste große Flaschenhals ab. Neue KI-Rechenzentren benötigen nicht mehr einige Megawatt, sondern zum Teil mehrere Gigawatt Leistung – so viel wie mehrere moderne Kernkraftwerksblöcke.

Damit beginnt ein weltweites Wettrennen um verfügbare Stromkapazitäten. Hyperscaler sichern sich bereits über langfristige Verträge gewaltige Energiemengen, während Stromnetze und Erzeugungskapazitäten mit dem Ausbau kaum Schritt halten können. Zusätzlich verschärfen geopolitische Risiken rund um den Iran-Krieg und die Straße von Hormus die Situation.

Für Energieversorger und ihre Zulieferer könnte damit ein goldenes Zeitalter beginnen. Steigende Nachfrage, langfristige Abnahmeverträge und wachsende Strompreise schaffen ein Umfeld, in dem ausgewählte Unternehmen zum nächsten großen KI-Trade werden könnten.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die besonders stark vom explodierenden Energiehunger der KI profitieren könnten – und bei Anlegern bislang teilweise noch unter dem Radar laufen.

Jetzt den kostenlosen Report sichern – und die nächsten Gewinner des KI-Booms entdecken!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.